Trial Profile
A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 08 Feb 2018 New trial record